GlassScriptPhysician profile
Christine Torres
NPI 1104409481
$2,839.92
in general payments reported to CMS, 2019-2025
21 companies · $777 in 2025
The $777 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $199 · 2023: $648 · 2024: $934 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $548.16 | 2023-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $335.31 | 2021-2024 | |
| Travere Therapeutics, INC. | $264.00 | 2024-2025 | Filspari |
| Calliditas Therapeutics US INC. | $182.91 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $180.63 | 2022-2025 | Veltassa |
| Akebia Therapeutics INC | $136.90 | 2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $133.56 | 2025 | |
| Mallinckrodt Hospital Products INC. | $122.79 | 2025 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $122.79 | 2024 | Jynarque |
| Ani Pharmaceuticals, INC. | $122.79 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.07 | 2024 | Jardiance |
| Puma Biotechnology, INC. | $106.17 | 2023 | |
| Horizon Therapeutics Plc | $98.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $94.29 | 2021 | |
| Fresenius USA Marketing, INC. | $68.42 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.49 | 2022 | |
| Baxter Healthcare | $48.68 | 2024 | Renal - Pd |
| Nxstage Medical, INC. | $34.75 | 2023 | Liberty Select Cycler, Nxstage System One |
| Ardelyx, INC. | $32.15 | 2025 | Xphozah 30 Mg |
| Ironshore Pharmaceuticals INC. | $18.09 | 2024 | |
| Abbvie INC. | $15.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.